AREXVY

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: eaf60d0a363f2887
Drug Approval Canada Name: AREXVY
Product Name: AREXVY
Status: Marketed
Status Date: 2023-09-06
Original Market Date: 2023-09-06
Din: 02540207
Drug Class: Human
Dosage Form: Powder For Suspension
Route Of Administration: Intramuscular
Schedule: Schedule D
Ahfs: 80:12.00
Atc Original: J07BX05 RESPIRATORY SYNCYTIAL VIRUS VACCINE
Atc Name: j 07 bx 05
Aig Number: 0164921001
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

RESPIRATORY SYNCYTIAL VIRUS PREFUSION F PROTEIN (RSVPREF3)

120 MCG / 0.5 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

eaf60d0a363f2887

Type

Standard